| | | |
每股
|
| |
總計
|
| ||||||
|
公開發行價(1)
|
| | |
US$
|
9.250
|
| | | |
US$
|
153,000,004
|
| |
|
承保折扣和佣金(2)
|
| | |
US$
|
0.555
|
| | | |
US$
|
9,180,000
|
| |
|
給Bellus Health Inc.的收益(未計費用)
|
| | |
US$
|
8.695
|
| | | |
US$
|
143,820,004
|
| |
| 傑富瑞 | | |
Evercore ISI
|
| |
加拿大皇家銀行資本市場
|
|
|
承銷商的立場
|
| |
MAXIMUM SIZE
|
| |
鍛鍊週期
|
| |
行權價
|
|
| 購買額外普通股的選擇權 | | | 2,481,081 common shares | | | 本招股説明書附錄日期後30日 | | | 每股普通股9.25美元 | |
|
目錄
|
| | | | | | |
|
招股説明書副刊
|
| | |||||
|
GENERAL MATTERS
|
| | |
|
S-1
|
| |
|
招股説明書補充摘要
|
| | |
|
S-3
|
| |
|
THE OFFERING
|
| | |
|
S-16
|
| |
|
RISK FACTORS
|
| | |
|
S-17
|
| |
|
USE OF PROCEEDS
|
| | |
|
S-42
|
| |
|
DIVIDEND POLICY
|
| | |
|
S-43
|
| |
| CAPITALIZATION | | | |
|
S-44
|
| |
|
有關前瞻性陳述的警告
|
| | |
|
S-45
|
| |
|
PRIOR SALES
|
| | |
|
S-49
|
| |
|
成交價和成交量
|
| | |
|
S-50
|
| |
|
加拿大聯邦所得税的某些考慮因素
|
| | |
|
S-51
|
| |
|
針對美國持有者的某些重要的美國聯邦所得税考慮因素
|
| | |
|
S-55
|
| |
| UNDERWRITING | | | |
|
S-61
|
| |
|
民事責任的可執行性
|
| | |
|
S-69
|
| |
|
LEGAL MATTERS
|
| | |
|
S-70
|
| |
|
審計師、轉讓代理和登記員
|
| | |
|
S-70
|
| |
|
通過引用併入的文檔
|
| | |
|
S-71
|
| |
|
作為註冊聲明的一部分提交的文件
|
| | |
|
S-73
|
| |
|
您可以在哪裏找到更多信息
|
| | |
|
S-74
|
| |
|
證券法規定的豁免
|
| | |
|
S-75
|
| |
|
執行鍼對外國人士或公司的判決
|
| | |
|
S-75
|
| |
|
MARKETING MATERIALS
|
| | |
|
S-76
|
| |
|
Bellus Health Inc.證書
|
| | |
|
C-1
|
| |
|
承銷商證書
|
| | |
|
C-2
|
| |
|
ABOUT THIS PROSPECTUS
|
| | |
|
1
|
| |
|
財務信息
|
| | |
|
2
|
| |
|
其他信息
|
| | |
|
2
|
| |
|
通過引用併入的文檔
|
| | |
|
4
|
| |
|
作為美國註冊聲明的一部分提交的文件
|
| | |
|
6
|
| |
|
前瞻性陳述
|
| | |
|
7
|
| |
|
THE COMPANY
|
| | |
|
10
|
| |
|
RECENT DEVELOPMENTS
|
| | |
|
10
|
| |
|
BUSINESS OF THE COMPANY
|
| | |
|
12
|
| |
|
合併資本化
|
| | |
|
19
|
| |
|
USE OF PROCEEDS
|
| | |
|
20
|
| |
|
SELLING SHAREHOLDERS
|
| | |
|
21
|
| |
|
PLAN OF DISTRIBUTION
|
| | |
|
22
|
| |
|
加拿大和美國聯邦所得税的某些考慮因素
|
| | |
|
23
|
| |
|
加拿大聯邦所得税的某些考慮因素
|
| | |
|
24
|
| |
|
美國聯邦所得税對美國持有者的重要考慮因素
|
| | |
|
28
|
| |
|
股本説明
|
| | |
|
34
|
| |
|
BOOK-BASED SYSTEM
|
| | |
|
35
|
| |
|
普通股成交價和成交量
|
| | |
|
35
|
| |
|
PRIOR SALES
|
| | |
|
35
|
| |
|
RISK FACTORS
|
| | |
|
36
|
| |
|
LEGAL MATTERS
|
| | |
|
58
|
| |
|
審計師、轉讓代理和登記員
|
| | |
|
58
|
| |
|
執行鍼對外國人士或公司的判決
|
| | |
|
58
|
| |
|
購買者的法定撤銷權和撤銷權
|
| | |
|
58
|
| |
|
公司證書
|
| | |
|
60
|
| |
劑量
|
| |
安慰劑調整後
變化 在24小時內 咳嗽 頻率 在第28天 |
| |
P值
|
| ||||||
12.5毫克,出價
|
| | |
|
-21.1%
|
| | | |
|
p=0.098
|
| |
50 mg Bid
|
| | |
|
-34.4%
|
| | | |
|
p=0.003
|
| |
200 mg Bid
|
| | |
|
-34.2%
|
| | | |
|
p=0.005
|
| |
DOSE
|
| |
PLACEBO-ADJUSTED
REDUCTION IN AWAKE COUGH FREQUENCY |
| |
P-VALUE
|
| ||||||
25 mg Bid
|
| | |
|
-11%
|
| | | |
|
p=0.14
|
| |
50 mg Bid
|
| | |
|
-6%
|
| | | |
|
p=0.46
|
| |
100 mg Bid
|
| | |
|
-8%
|
| | | |
|
p=0.41
|
| |
200 mg Bid
|
| | |
|
-17%
|
| | | |
|
p=0.09
|
| |
劑量
|
| |
安慰劑調整後
減量 在覺醒中 咳嗽 頻率 |
| |
P值
|
| ||||||
25 mg Bid
|
| | |
|
-20%
|
| | | |
|
p=0.0010
|
| |
50 mg Bid
|
| | |
|
-18%
|
| | | |
|
p=0.0186
|
| |
100 mg Bid
|
| | |
|
-19%
|
| | | |
|
p=0.0320
|
| |
200 mg Bid
|
| | |
|
-27%
|
| | | |
|
p=0.0026
|
| |
劑量
|
| |
安慰劑調整後
減量 在覺醒中 咳嗽 頻率 |
| |
P值
|
| ||||||
25 mg Bid
|
| | |
|
-28%
|
| | | |
|
p=0.0005
|
| |
50 mg Bid
|
| | |
|
-28%
|
| | | |
|
p=0.0003
|
| |
100 mg Bid
|
| | |
|
-30%
|
| | | |
|
p=0.0014
|
| |
200 mg Bid
|
| | |
|
-32%
|
| | | |
|
p=0.0006
|
| |
PURPOSE
|
| |
預估金額
|
|
BLU-5937治療慢性咳嗽的臨牀試驗
|
| |
US$ 82.0 million
|
|
製造、配方和放大
|
| |
US$29.7 million
|
|
其他項目成本
|
| |
1,800萬美元
|
|
營運資金和一般行政管理
|
| |
1,320萬美元
|
|
| | |
截至2022年3月31日
|
| |||||||||
| | |
實際
|
| |
調整後的
|
| ||||||
| | |
(未經審計)
(單位:千美元) |
| |||||||||
現金和現金等價物
|
| | |
$
|
147,155
|
| | | |
$
|
290,052
|
| |
短期投資
|
| | |
|
86,813
|
| | | |
|
86,813
|
| |
總計
|
| | |
$
|
233,968
|
| | | |
$
|
376,865
|
| |
Shareholders’ Equity | | | | | | | | | | | | | |
股本(已發行普通股 - 106,744,431;AS
adjusted – 123,284,972) |
| | |
$
|
800,015
|
| | | |
$
|
953,015
|
| |
其他權益
|
| | |
|
39,156
|
| | | |
|
39,156
|
| |
赤字
|
| | |
|
(568,676)
|
| | | |
|
(578,779)
|
| |
累計其他綜合收益
|
| | |
|
9,298
|
| | | |
|
9,298
|
| |
股東權益總額
|
| | |
|
279,793
|
| | | |
|
422,690
|
| |
總市值
|
| | |
$
|
279,793
|
| | | |
$
|
422,690
|
| |
|
DATE OF GRANT
|
| |
NUMBER OF
OPTIONS ISSUED |
| |
EXERCISE PRICE
(PER OPTION) |
|
August 11, 2021
|
| |
20,000
|
| |
US$3.10
|
|
2021年11月10日
|
| |
180,000
|
| |
US$7.04
|
|
2022年2月23日
|
| |
2,945,000
|
| |
US$7.01
|
|
March 23, 2022
|
| |
390,000
|
| |
US$6.38
|
|
May 11, 2022
|
| |
220,000
|
| |
US$7.85
|
|
July 6, 2022
|
| |
200,000
|
| |
US$9.58
|
|
DATE OF ISSUANCE
|
| |
NUMBER OF
SHARES ISSUED |
| |
EXERCISE PRICE
(PER OPTION OR SHARE, (br}視情況而定) |
|
2021年11月4日
|
| |
888
|
| |
Cdn$1.80
|
|
2021年11月4日
|
| |
7,778
|
| |
Cdn$1.08
|
|
2021年11月8日
|
| |
7,000
|
| |
Cdn$1.80
|
|
2021年12月14日
|
| |
25,000,000
|
| |
US$8.00
|
|
2021年12月23日
|
| |
33,334
|
| |
Cdn$1.08
|
|
2021年12月23日
|
| |
4,000
|
| |
Cdn$3.14
|
|
2021年12月29日
|
| |
3,000,000
|
| |
US$8.00
|
|
2022年1月10日
|
| |
4,111
|
| |
Cdn$1.80
|
|
2022年1月11日
|
| |
3,000
|
| |
Cdn$1.80
|
|
2022年2月17日
|
| |
5,667
|
| |
Cdn$3.78
|
|
March 1, 2022
|
| |
118,520
|
| |
Cdn$1.80
|
|
March 1, 2022
|
| |
86,720
|
| |
Cdn$1.80
|
|
March 3, 2022
|
| |
20,833
|
| |
Cdn$1.80
|
|
March 3, 2022
|
| |
11,111
|
| |
Cdn$1.08
|
|
March 3, 2022
|
| |
16,666
|
| |
Cdn$1.26
|
|
March 22, 2022
|
| |
87,442
|
| |
Cdn$1.80
|
|
April 8, 2022
|
| |
2,072
|
| |
Cdn$3.14
|
|
April 19, 2022
|
| |
1,301
|
| |
Cdn$3.58
|
|
May 20, 2022
|
| |
23,490
|
| |
Cdn$1.26
|
|
| | |
TSX
|
| |
NASDAQ COMPOSITE
|
| ||||||||||||||||||||||||||||||
| | |
HIGH
|
| |
LOW
|
| |
VOLUME
|
| |
HIGH
|
| |
LOW
|
| |
VOLUME
|
| ||||||||||||||||||
| | |
(CDN$)
|
| |
(CDN$)
|
| |
(#)
|
| |
(US$)
|
| |
(US$)
|
| |
(#)
|
| ||||||||||||||||||
2021年7月
|
| | |
|
4.00
|
| | | |
|
3.32
|
| | | |
|
689,987
|
| | | |
|
3.22
|
| | | |
|
2.60
|
| | | |
|
10,274,074
|
| |
2021年8月
|
| | |
|
4.82
|
| | | |
|
3.54
|
| | | |
|
852,624
|
| | | |
|
3.83
|
| | | |
|
2.82
|
| | | |
|
10,059,420
|
| |
2021年9月
|
| | |
|
9.31
|
| | | |
|
4.42
|
| | | |
|
6,012,205
|
| | | |
|
7.35
|
| | | |
|
3.50
|
| | | |
|
115,635,428
|
| |
2021年10月
|
| | |
|
9.25
|
| | | |
|
7.10
|
| | | |
|
2,171,242
|
| | | |
|
7.48
|
| | | |
|
5.68
|
| | | |
|
16,812,714
|
| |
2021年11月
|
| | |
|
9.47
|
| | | |
|
6.91
|
| | | |
|
1,701,319
|
| | | |
|
7.65
|
| | | |
|
5.41
|
| | | |
|
23,184,217
|
| |
2021年12月
|
| | |
|
12.59
|
| | | |
|
6.64
|
| | | |
|
3,968,455
|
| | | |
|
9.84
|
| | | |
|
5.18
|
| | | |
|
153,383,543
|
| |
2022年1月
|
| | |
|
10.55
|
| | | |
|
6.30
|
| | | |
|
2,775,604
|
| | | |
|
8.21
|
| | | |
|
4.98
|
| | | |
|
22,294,330
|
| |
2022年2月
|
| | |
|
9.40
|
| | | |
|
7.23
|
| | | |
|
2,357,964
|
| | | |
|
7.45
|
| | | |
|
5.61
|
| | | |
|
28,447,599
|
| |
2022年3月
|
| | |
|
8.85
|
| | | |
|
7.00
|
| | | |
|
1,601,946
|
| | | |
|
7.11
|
| | | |
|
5.45
|
| | | |
|
10,156,932
|
| |
2022年4月
|
| | |
|
11.29
|
| | | |
|
8.46
|
| | | |
|
2,040,624
|
| | | |
|
9.04
|
| | | |
|
6.76
|
| | | |
|
17,818,288
|
| |
May 2022
|
| | |
|
11.68
|
| | | |
|
8.07
|
| | | |
|
3,830,869
|
| | | |
|
9.09
|
| | | |
|
6.35
|
| | | |
|
17,888,269
|
| |
2022年6月
|
| | |
|
13.25
|
| | | |
|
9.18
|
| | | |
|
2,040,276
|
| | | |
|
10.28
|
| | | |
|
7.08
|
| | | |
|
19,689,433
|
| |
2022年7月(至7月13日)
|
| | |
|
14.46
|
| | | |
|
11.61
|
| | | |
|
1,383,789
|
| | | |
|
11.10
|
| | | |
|
8.82
|
| | | |
|
9,783,208
|
| |
承銷商
|
| |
數
普通股 |
| |||
Jefferies LLC
|
| | |
|
6,616,217
|
| |
Evercore Group L.L.C.
|
| | |
|
4,962,163
|
| |
加拿大皇家銀行資本市場有限責任公司
|
| | |
|
2,811,891
|
| |
生活科學資本有限責任公司
|
| | |
|
2,150,270
|
| |
總計
|
| | |
|
16,540,541
|
| |
|
| | |
每股
|
| |
共計
|
| ||||||
| | |
如果沒有
購買選擇權 增發股份 |
| |
與.一起
購買選擇權 增發股份 |
| |
如果沒有
購買選擇權 增發股份 |
| |
與.一起
購買選擇權 增發股份 |
|
公開發行
價格 |
| | US$9.250 | | | US$9.250 | | | US$153,000,004 | | | US$175,950,004 | |
我們支付的承保折扣和佣金 | | | US$0.555 | | | US$0.555 | | | US$ 9,180,000 | | | US$ 10,557,001 | |
扣除費用前的收益給我們
|
| | US$8.695 | | | US$8.695 | | | US$143,820,004 | | | US$165,393,003 | |
|
(Signed) ROBERTO BELLINI
總裁與首席執行官 |
| |
(Signed) RAMZI BENAMAR
首席財務官 |
|
|
(簽名)Francesco Bellini博士
董事 |
| |
(Signed) PIERRE LAROCHELLE
董事 |
|
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
財務信息
|
| | | | 2 | | |
|
其他信息
|
| | | | 2 | | |
|
通過引用併入的文檔
|
| | | | 4 | | |
|
作為美國註冊聲明的一部分提交的文件
|
| | | | 6 | | |
|
前瞻性陳述
|
| | | | 7 | | |
|
THE COMPANY
|
| | | | 10 | | |
|
RECENT DEVELOPMENTS
|
| | | | 10 | | |
|
BUSINESS OF THE COMPANY
|
| | | | 12 | | |
|
合併資本化
|
| | | | 19 | | |
|
USE OF PROCEEDS
|
| | | | 20 | | |
|
SELLING SHAREHOLDERS
|
| | | | 21 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 22 | | |
|
加拿大和美國聯邦所得税的某些考慮因素
|
| | | | 23 | | |
|
加拿大聯邦所得税的某些考慮因素
|
| | | | 24 | | |
|
美國聯邦所得税對美國持有者的重要考慮因素
|
| | | | 28 | | |
|
股本説明
|
| | | | 34 | | |
|
BOOK-BASED SYSTEM
|
| | | | 35 | | |
|
普通股成交價和成交量
|
| | | | 35 | | |
|
PRIOR SALES
|
| | | | 35 | | |
|
RISK FACTORS
|
| | | | 36 | | |
|
LEGAL MATTERS
|
| | | | 58 | | |
|
審計師、轉讓代理和登記員
|
| | | | 58 | | |
|
執行鍼對外國人士或公司的判決
|
| | | | 58 | | |
|
購買者的法定撤銷權和撤銷權
|
| | | | 58 | | |
|
公司證書
|
| | | | 60 | | |
Dose
|
| |
Placebo-adjusted
reduction in awake cough frequency |
| |
P-value
|
| ||||||
25mg BID
|
| | | | -11% | | | | | | p=0.14 | | |
50mg BID
|
| | | | -6% | | | | | | p=0.46 | | |
100mg BID
|
| | | | -8% | | | | | | p=0.41 | | |
200mg BID
|
| | | | -17% | | | | | | p=0.09 | | |
Dose
|
| |
Placebo-adjusted
reduction in awake cough frequency |
| |
P-value
|
| ||||||
25mg BID
|
| | | | -20% | | | | | | p=0.0010 | | |
50mg BID
|
| | | | -18% | | | | | | p=0.0186 | | |
100mg BID
|
| | | | -19% | | | | | | p=0.0320 | | |
200mg BID
|
| | | | -27% | | | | | | p=0.0026 | | |
Dose
|
| |
Placebo-adjusted
reduction in awake cough frequency |
| |
P-value
|
| ||||||
25mg BID
|
| | | | -28% | | | | | | p=0.0005 | | |
50mg BID
|
| | | | -28% | | | | | | p=0.0003 | | |
100mg BID
|
| | | | -30% | | | | | | p=0.0014 | | |
200mg BID
|
| | | | -32% | | | | | | p=0.0006 | | |
|
(Signed) R奧貝託·貝裏尼
總裁和首席執行官 |
| |
(Signed) 拉姆齊·貝納馬爾
首席財務官 |
|
|
(Signed) Dr F貝裏尼
Director |
| |
(Signed) P艾爾·拉羅切爾
Director |
|